喹诺酮过敏

Edoabasi U. McGee, Essie Samuel, Bernadett Boronea, Nakoasha Dillard, Madison N Milby, S. Lewis
{"title":"喹诺酮过敏","authors":"Edoabasi U. McGee, Essie Samuel, Bernadett Boronea, Nakoasha Dillard, Madison N Milby, S. Lewis","doi":"10.3390/pharmacy7030097","DOIUrl":null,"url":null,"abstract":"Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available.","PeriodicalId":19920,"journal":{"name":"Pharmacy: Journal of Pharmacy Education and Practice","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":"{\"title\":\"Quinolone Allergy\",\"authors\":\"Edoabasi U. McGee, Essie Samuel, Bernadett Boronea, Nakoasha Dillard, Madison N Milby, S. Lewis\",\"doi\":\"10.3390/pharmacy7030097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available.\",\"PeriodicalId\":19920,\"journal\":{\"name\":\"Pharmacy: Journal of Pharmacy Education and Practice\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"22\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy: Journal of Pharmacy Education and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmacy7030097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy: Journal of Pharmacy Education and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharmacy7030097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

摘要

喹诺酮类药物是与药物引起的过敏反应相关的第二大常见抗生素,但关于喹诺酮类药物过敏的数据很少。本文综述了喹诺酮类药物过敏的现有证据,包括患病率、危险因素、诊断、临床表现、交叉反应性和过敏反应的处理。尽管喹诺酮类药物过敏的发生率仍然低于β -内酰胺类药物,但近几十年来,喹诺酮类药物过敏的报道越来越多,这很可能是由于喹诺酮类药物的广泛使用和莫西沙星的引入。在评估喹诺酮类药物过敏时,彻底的病史仍然是必要的。已经研究了许多诊断工具,但皮肤试验可能产生假阳性结果,体外试验尚未得到验证。药物激发试验被认为是确认喹诺酮类药物过敏的首选试验,但并非没有风险。关于喹诺酮类药物之间交叉反应的证据有限且相互矛盾。喹诺酮类药物过敏可表现为立即或延迟反应,但在整个类别中并不统一,莫西沙星具有最高的过敏反应风险。当过敏反应发生时,喹诺酮类药物应停用,并避免在未来的情况下使用,但如果没有其他替代药物,可能需要进行脱敏治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Quinolone Allergy
Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信